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CrystallographyAs compounds are optimized for greater potency during pharmaceutical discovery, their aqueous solubility often de-
creases,making them less viable as orally-administereddrugs. To investigatewhether potency and insolubility share
a commonorigin,weexamined the structural and thermodynamic properties of telaprevir, a sparingly soluble inhib-
itor of hepatitis C virus protease. Comparison of the hydrogen bond motifs in crystalline telaprevir with those
present in the protease–telaprevir complex revealed striking similarities. Additionally, the thermodynamics of
telaprevir dissolution closely resembles thoseof protein–liganddissociation. Together, theseﬁndings point to a com-
mon origin of potency and insolubility rooted in particular amide–amidehydrogen bondpatterns. The insolubility of
telaprevir is shown by computational analysis to be caused by interactions in the crystal, not unfavorable hydropho-
bic hydration. Accordingly, competing out the particular amide–amide hydrogen bond motifs in crystalline
telaprevir with 4-hydroxybenzoic acid yielded a co-crystalline solid with excellent aqueous dissolution and oral ab-
sorption. The analysis suggests a generalizable approach for identifyingdrug candidate compounds that either canor
cannot be rendered orally bioavailable by alteration of their crystalline solid phases, in an approach that provides a
pragmatic way to attain substantial enhancements in the success rate of drug discovery and development.
© 2014 Vertex Pharmaceuticals Incoporated. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).elly).
Published by Elsevier B.V. This is an o1. Introduction
Pharmaceutical R&D, even today, suffers from a notoriously low suc-
cess rate. A sizeable fraction of drug candidates fail, many because,pen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
101P.R. Connelly et al. / Biophysical Chemistry 196 (2015) 100–108although they are potent in vitro, their physical properties are poorly
suited to becoming medicines [1,2]. These failures impose a severe cost
on society, resulting both inmore expensive health care and in otherwise
preventable suffering [3]. Of these physical properties, aqueous solubility
may cause themost trouble, owing to a conundrumwidely known in the
pharmaceutical industry: as compounds are optimized for higher poten-
cy, they tend to become less soluble in water [4]. Compounds with poor
aqueous solubility generally fail to reach a concentration in the gastroin-
testinal tract that is sufﬁcient for absorption into the systemic circulation,
whichmakes themunusable as orally-administered drugs. The potency–
insolubility conundrum has prompted speculation, concern, and at-
tempts to taxonomize the problemormanage itwith trial-and-error em-
piricism (including correlationswith octanolwater partition coefﬁcients,
Lipinski's Rule of 5 and the Biopharmaceutical Classiﬁcation System) [2,
5]. However, a fundamental molecular level thermodynamic connection
between these two properties has yet to be elucidated.
Given how often drug discovery results in compounds that are both
potent and insoluble, we wondered whether these properties might
share some common origin. On a general level, potency and insolubility
both reﬂect the stability of supramolecular structures formed by the
drug. A potent drug forms a stable protein–drug complex, i.e., a complex
with an unfavorable free energy of dissociation. Similarly, an insoluble
drug forms a stable crystal, i.e., a crystal with an unfavorable free energy
of dissolution. The processes of dissociation (for protein–drug com-
plexes) and dissolution (for crystals of drug) are expressed formally
by the following equilibria:
KD;Δ JD
PX aqð Þ → P aqð Þ þ X aqð Þ ð1Þ
KS;Δ JS
X sð Þ → X aqð Þ: ð2Þ
For both processes, general thermodynamic changes (ΔJD [dissocia-
tion] or (ΔJS [dissolution]) reﬂect the breakdown of noncovalent inter-
actions in the supramolecular structures from their initial states
(PX(aq) for the protein–drug complex and X(s) for the crystalline
solid drug) and the formation of new interactions in their ﬁnal states
(unliganded protein, P(aq), and free drug in solution, X(aq)). With
these broad structural and thermodynamic similarities in mind, we
sought a system in which the conundrum manifested itself so that we
could explore it in detail at the atomic level.
The consequences of the potency–insolubility conundrum be-
came clear during the discovery and development of telaprevir
(Fig. 1a), a small-molecule inhibitor of hepatitis C virus (HCV) pro-
tease [6,7]. Telaprevir binds tightly to HCV protease (KD = ~30 nM
at 37 ° C) but has low aqueous solubility. When stabilized as a
high-energy amorphous form, the compound becomes much more
soluble; this form was recently approved (as Incivek) to treat HCV
infection. However, telaprevir required 20 challenging and costly
years of R&D. In order to better understand the conundrum, and to
solve it in a way that may be useful to streamline future work on po-
tent and insoluble compounds, we studied the structural and ther-
modynamic properties of telaprevir and its target, the NS3
protease of HCV.
2. Results
The NS3 protease, like many proteases, has an active site composed
substantially of apolar residues, with 355.7 Å of apolar surface area
(52.5% of the total). Thus, successful competitive inhibitors of NS3 are
likely to display an apolar surface aswell. Apolar surfaces interact stably
with each other as dehydration and packing effects lower the free ener-
gy of interaction. In addition, they create a felicitous environment for
hydrogen bonds to formbetween amides on the inhibitor and backboneamides on the protease. The hydrophobic environment protects hydro-
gen bonds from the surrounding water and lowers the local dielectric,
which results in tighter hydrogen bonds and a more stable protein–
drug complex [8–10]. Amide–amide hydrogen bonds, in particular, are
known to be crucial tomany protein–drug interactions, protein–protein
interactions, and protein folding [9].
We investigated the patterns of hydrogen bonds between NS3 prote-
ase and telaprevir in the manner of Etter et al. [11]. Strikingly, we deter-
mined that the very same pattern of amide–amide hydrogen bonds that
composes the crystalline drug also forms in the protein–drug complex
(Fig. 1). In crystalline telaprevir, these bonds create two fused supramo-
lecular ring systems comprising 10 and 12 ring atoms, respectively, each
ring system employing two hydrogen bond donors and two acceptors, as
depicted in Fig. 1B. In graph set notation, these interactions are referred
to as R2,2(10) and R2,2(12) to indicate rings containing 2 hydrogen
bond donors and 2 hydrogen bond acceptors with 10 atoms and 12
atoms in the rings, respectively. Hydrogen bonds form between i) the
amide oxygen and the proton on the terminal amidenitrogen, ii) the pro-
ton on the amide nitrogen and the adjacent activated ketone oxygen, and
iii) the amide oxygen and the proton on the amide nitrogen. The same
amide groups participate in the bond between the telaprevir and the
NS3 protease, creating an identical 10 atom ring structure constructed
from two hydrogen bond donors and two acceptors (Fig. 1C). In addition,
other aspects of the supramolecular architectures of crystalline telaprevir
(viz., a 12-atom ring motif constructed from two hydrogen bond donors
and two acceptors) and the NS3–telaprevir complex (a 14 member ring
motif constructed from two hydrogen bond donors and two hydrogen
bond acceptors — R2,2(14)) are not only similar to each other, but also
isostructural to parallel and anti-parallel β-sheets, respectively, in folded
proteins. Further, in crystalline telaprevir, dimers joined by 10-member
ring motifs form the basic unit of a structural hierarchy: the dimers as-
semble into rods, the rods into sheets, and the sheets into stacks (as
shown in Fig. 1D–F). This stacked structure of crystalline telaprevir has
a packing density of 0.7, close to the average packing density of the
NS3–telaprevir complex (0.8) and of folded proteins generally (0.75)
[12–13]. Taken together, these similarities emphasize that crystalline
telaprevir and the telaprevir–protease complex share several structural
features in common, structural features that are also shared by folded
proteins. This commonality suggests a preliminary explanation for the
potency–insolubility conundrum: a drug that binds tightly to NS3 prote-
ase, like telaprevir, may also bind tightly to itself, resulting in a stable, in-
soluble crystal. Thus, optimizing potency may also mean, unwittingly,
optimizing the stability of the crystalline drug.
To investigate the energetic relationship between potency and insol-
ubility, we studied the thermodynamics of transfer of crystalline
telaprevir to water. The very low aqueous solubility (~7 μmol) and
the rate of dissolution of crystalline telaprevir made direct calorimetric
measurements for heats of solution inaccessible by experiment
(i.e., below the detection limits of even the most sensitive calorimeters
available). Therefore, to characterize the thermodynamics of dissolu-
tion, we determined the solubility of telaprevir in water across the tem-
perature range of 5°–65 °C to high precision (Fig. 2a). To analyze the
dissolution thermodynamics of telaprevir, it is crucial to take into ac-
count all the species that form in solution from three reversible reac-
tions as follows: i) epimerization of the stereocenter adjacent to the
ketone, ii) hydration of the ketone, and iii) hydration of the ketone of
the epimer. The Supplementary information details the experimental
approach used to deconvolute the thermodynamic parameters of disso-
lution from those for hydration of the ketone (which implemented
cryo-probe NMR spectroscopy) and epimerization (which implement-
ed liquid chromatography).
In three aspects, telaprevir's thermodynamics of dissolution (or, for-
mally, the transfer from the crystal to aqueous solution, Nxtal→ Naq in
Table 1) closely resembles the processes of protein unfolding and
protein–ligand dissociation. First, the van't Hoff plot in Fig. 2a shows dis-
tinct curvature as dissolution takes place with a large positive heat
Fig. 1. Structural features of telaprevir. Nitrogen atoms are highlighted in blue and oxygen atoms in red. A) Telaprevir structure, showing natural charges (positive, blue; negative, red) as
calculated by NBO 5.9 [24]. B) The parallel telaprevir dimer forms ringmotifs of R2,2(10) and R2,2(12) graph sets. C) Telaprevir binds similarly to NS3 protease, formingmotifs of R2,2(10)
and R2,2(14) graph sets. D–F) Structural hierarchy of telaprevir: telaprevir dimers assemble into rods (D), the rods into sheets (E), and the sheets into stacks (F).
102 P.R. Connelly et al. / Biophysical Chemistry 196 (2015) 100–108capacity change (ΔCp=260±70 cal/K-mol), which is accounted for by
the changes in solvent-accessible polar and nonpolar surface areas from
crystalline to solution states. (The value calculated using the method of
surface area coefﬁcients [14] is 330 cal/K-mol.) A large positive heat ca-
pacity change has been observed in the aqueous dissolution of other
crystalline systems and, importantly, is a common feature of other
noncovalent supramolecular disassembly processes including protein
unfolding, protein–peptide dissociation, and the dissociation of many
protein–drug complexes [15–17]. (ΔCp for the dissociation of telaprevir
and NS3 protease is estimated to be 106 cal/K-mol [see Supplement].)
Second, the ratio of the entropy change to the heat capacity change
(ΔS/ΔCp= 0.2 at 25 °C) is remarkably close to that observed for protein
unfolding and the aqueous dissolution of nonpolar gases, liquid hydro-
carbons, and hydrophobic crystalline cyclic dipeptides (see inset in
Fig. 2b). Lastly, the stability of both crystalline telaprevir and the
telaprevir–NS3 complex, as given by the free energy of dissolution/dis-
sociation in water, has a maximum in temperature of 87 °C (Fig. 2B).
Other processes that exhibit this stability phenomenon include the
cold and heat denaturation of proteins, dissociation of protein–peptide
complexes and telaprevir–NS3 binding (see Supplement) [18–20]. In
sum, while the protein–drug interaction of NS3 and telaprevir is struc-
turally and energetically comparable to other assembly processes in-
volving proteins (protein–protein interactions and protein folding),
it is also structurally and energetically comparable to the drug–drug
interaction that stabilizes crystalline telaprevir. Thus, potency and insol-
ubility seem to derive from a common origin that includes the sameamide–amide hydrogen bond patterns, sheltered by a hydrophobic
microenvironment.
To relate the observed thermodynamics of dissolution of telaprevir to
the structural features that stabilize its crystal, and to determine why the
crystalline form of the drug is so insoluble in water, we calculated the
thermodynamics of dissolution in a two-step process. First, we used mo-
lecular mechanics and normal mode analysis to calculate the thermody-
namic parameters (ΔG, ΔH, ΔS, and ΔCp) for the transfer of telaprevir
from its crystal to the vapor phase; then we used a molecular
dynamics/free-energy perturbation technique to calculate the thermody-
namics for transfer from the vapor phase to solution [21–23]. Table 1 de-
tails the net results for comparison to the experimental values of
thermodynamic parameters, and the supplementary information details
the computational methods employed. The magnitudes of the free ener-
gies of transfer from crystal to vapor are large and positive, while those
from vapor to water are large and negative. These ﬁndings clearly dem-
onstrate that the stability of the crystal lattice (ΔGxtal → vapor), rather
than the compound's aversion towater (ΔGvapor→ aqueous), is responsible
for the insolubility of telaprevir. Of the structural factors that contribute
to insolubility, electrostatic and dispersion interactions amongmolecules
of telaprevir in the crystal lattice are the largest (i.e., values of ΔG =
44 kcal/mol andΔG=22 kcal/mol for electrostatic and dispersion inter-
actions for the transfer of crystal to vapor, respectively, Table S3).
Having concluded that the interactions in crystalline telaprevir are
principally responsible for its insolubility,wehypothesized, as a practical
corollary, that interrupting the hydrogen bonding and packing that
1 This study examined what is often termed “kinetic solubility” or “effective solubility”
of the co-crystal, rather than the true thermodynamic solubility of the co-crystal in water.
Formally, the solution produced by dissolving the co-crystal in water is supersaturated
with respect to telaprevir and the co-crystal must be stabilized by adding polymers to
the dosing suspension (see SI Appendix). At equilibrium the co-crystal will, over time, un-
dergo a solvent-mediated phase transition to neat telaprevir and the amounts of com-
pound in solution will decrease accordingly to that of neat telaprevir. This transition is
slow so that the effective solubility of telaprevir in aqueous solution produced by dissolv-
ing the co-crystal is high. In vitro experiments in which excess co-crystalline solid is ad-
ministered to simulated gastric ﬂuid at 37 °C show that the concentration of drug in
solution for up to 3 h is enhanced many 100-fold over that of neat crystalline telaprevir.
Stabilization of supersaturation of aqueous co-crystal suspensions by the addition of poly-
mers is a commonly observed effect; however, the precisemechanismof such stabilization
requires further investigation.
Fig. 2. Thermodynamics of telaprevir dissolution in water. A) van't Hoff plot showing the
retrograde temperature-dependent solubility for telaprevir in water. Curve is ﬁtted to ex-
perimental results, quantiﬁed by HPLC, with parameters reported in Table 1. See Supple-
ment for experimental details. B) Thermodynamic functions for the transfer of
crystalline telaprevir to water, showing behavior similar to that for protein unfolding
and protein–ligand dissociation. The labels indicate the functions for enthalpy ( H°), en-
tropy (T S°), and free energy ( G°) of dissolution. The inset shows relationships between
change in entropy and change in heat capacity at constant pressure for the dissolution in
water of rare gases (x), saturated hydrocarbons (○), liquid hydrocarbons (●), solid cyclic
peptides (□), and crystalline telaprevir (red). The dotted line represents a linear ﬁt of data
for the unfolding of 11 proteins [17].
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enhancing the effective aqueous solubility of the compound.We focused
on the common hydrogen bond motif – the ten atom ring system con-
structed from hydrogen bonds formed between the proton of the nitro-
gen and theoxygen of the amides straddling the tert-butyl group – found
in both the crystal of telaprevir and the NS3–telaprevir complex. We
evaluated the natural charge on all amide units using NBO 5.9 and
found that the oxygen adjacent to the octahydrocyclopenta[b]pyrrole
ring had the most negative natural charge. Correspondingly, the nitro-
gen of the same amide bond was overwhelmingly more electropositive
than the other N atoms that could participate in hydrogen bonds
(Fig. 1A). This result is consistent with Etter's rules [11] and points to
this bond as the likely strongest hydrogen bond stabilizing both the crys-
tal of telaprevir and, perhaps, the NS3–telaprevir complex.
The above analysis suggests that using anothermolecule to interrupt
the crucial hydrogen bond and form a co-crystal may lead to a higher-energy, more soluble solid form. To that end, we tested a range of
amide- and carboxylic acid-containing compounds, which have the
ability to form ring motifs mimicking, and competing energetically
with, those formed in crystalline telaprevir. 4-Hydroxybenzoic acid (4-
HBA) was found to form a 1:1 co-crystal with telaprevir that contained
the expected similar supermolecular ring structure in place of the previ-
ous O–HN interaction (Fig. 3a). (Experimental details are provided in
the Supplement.) As in the neat crystal, telaprevir dimers assemble
into rows, then sheets (Fig. 3b–c); however, in this case the stacking
of the sheets is interrupted by rows of 4-HBA that have bonded to indi-
vidual molecules of telaprevir (Fig. 3d). This co-crystal form displayed a
100-fold enhancement in effective solubility1 over that of neat crystal-
line telaprevir (Fig. 3e). Crucially, this increase in in vitro solubility
translates to an increase in in vivo exposure. When the telaprevir:4-
HBA co-crystal was dosed at 375 mg in dogs, it achieved an ~8-fold in-
crease in oral exposure over a suspension of neat crystalline telaprevir
(Fig. 3e). In fact, the integrated area under the curve of concentration
versus time demonstrates that the 4-HBA co-crystal achieves the same
exposure as the commercial tablet of telaprevir which contains an
amorphous form of the drug. Analysis of the pharmacokinetics (assum-
ing the measured effective solubility for the materials in simulated in-
testinal ﬂuid at 37 °C, and assuming permeability estimates scaled
from Caco-2 measurements) with an ACAT (advanced compartmental
absorption and transit) model reveals that the improved oral exposure
is a direct consequence of the enhanced effective aqueous solubility of
the 4-HBA co-crystal (see solid lines in Fig. 3e; detail in SI Appendix)
[26]. In the model, all disposition parameters (e.g., clearance, two com-
partment kinetic parameters, and permeability) are all constrained to
be the same between amorphous and co-crystalline telaprevir as de-
scribed in Materials & methods.
3. Discussion
Thus, the case of telaprevir is one example of how a potent, insoluble
drug can be rendered as a viable solid dosage form:we identiﬁed the su-
pramolecular structural similarity between the protein–drug complex
and the crystalline drug (the ten atom ring system comprised of 2 hy-
drogen bond donors and 2 acceptors), determined that the insolubility
of telaprevir was due to the strength of its crystal lattice –most notably
its hydrogen bonds – and interrupted these bonds with a competing
molecule. This approach may not be the only way to optimize both po-
tency and solubility: in some cases, it may be feasible to re-design the
covalent structure of the molecule so that its potency and solubility
are not driven by the same atoms. Further, in cases where a protein–
drug crystal structure is not available, structure–activity analyses may
still reveal the atoms responsible for potency. However, this solution
has the same prerequisite: understanding the structural origin of the
compound's insolubility, as demonstrated above.
Although our approach to telaprevir was successful, we recognize
that it is useful mainly insofar as it can be generalized to other com-
pounds. Further investigation revealed that telaprevir is far fromunique.
We examined the structures of several other drug compounds which
showed the same striking pattern, forming similar hydrogen bonding
Table 1
Measured, derived, and calculated values of the thermodynamic parameters of dissolution of telaprevir in aqueous solution. Keq, equilibrium constant; ΔG°, change in free energy; ΔH°,










N xtlð Þ⇌Kobs N aqð Þ þ H aqð Þ 8.7 ± 0.8 μM 6.91 ± 0.09 −11.5 ± 0.8 −62 ± 3 260 ± 70
N aqð Þ⇌KH H aqð Þ 8.0 ± 0.3 −1.23 ± 0.04 −5.5 ± 0.4 −14 ± 1 NAc
Derived valuesd
N xtlð Þ⇌Ksol N aqð Þ 1.0 ± 0.1 μM 8.2 ± 0.1 −5 ± 1 −45 ± 3 240 ± 70
Calculated valuese
N xtlð Þ⇌Ksol N aqð Þ 0.1 μM 9.4 ± 0.3 −8 ± 6 −55 Desmond 330
f
250 μM 4.9 26.9 73.8 Cosmo
4.3E7 M −10.4 11.6 73.8 ZAP
N gð Þ⇌Ksolv N aqð Þ 1.4E16 −18.9 ± 0.3 −67 ± 6 −146 Desmond
1.6E17 −23.4 −31.7 −27.8 Cosmo
3.0E28 −38.7 −47.0 −27.8 ZAP
N xtlð Þ⇌Kvap N gð Þ 1.5E−21 28.3 58.6 101
a N represents keto form, while H represents hydrated form. All thermodynamic parameters represent estimates from van't Hoff analysis at reference temperature of 298.15 °C.
b Data and ﬁts appear in supporting information.
c Data did not support ﬁtting with a heat capacity term.
d Equations used to derive these values and their derivations appear in supporting information. Errors represent the values determined by propagation.
e Values for free energy, enthalpy, and entropy were calculated using the computational methods described in the supplemental information.
f The value of the heat capacity was estimated using the relationship determined by Murphy and Gill.
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the three other HCV protease inhibitors. In each case, identical structural
similarities among their neat forms, complexes with HCV protease, and
co-crystals formed with carboxylic acids as those found with telaprevir
were revealed (see SI Appendix). In addition to HCV protease inhibitors,
we extended the analysis to the targets of classic insoluble drugs (viz.,
cyclosporine, celecoxib, tacrolimus andﬂuconazole), to theHIV protease
inhibitor ritonavir, and to the non-nucleoside HIV reverse transcriptase
inhibitor, efavirenz. In each case, similar hydrogen bondpatterns formed
between neat crystalline and protein-bound structures (see SI Appen-
dix). Efavirenz forms nearly identical hydrogen-bonding patterns in
theprotein–drug complex as it does in the thermodynamicallymost sta-
ble crystalline form (Fig. 3e): the protein–drug complex is connected by
a 9 member supermolecular ring system comprised of two hydrogen
bond donors and two hydrogen bond acceptors (R2,2(9)); the neat
efavirenz crystal is constructed from interacting 8 member rings utiliz-
ing the very same hydrogen bond donor and acceptor atoms. Moreover,
in two co-crystals of efavirenz, co-formers compete with the key hydro-
gen bond-forming unit to interrupt the principle structural motif in the
neat crystal — the same phenomenon that allowed us to create the co-
crystal of telaprevir with 4-hydroxybenzoic acid. The prevalence of
these hydrogen bonding trends across investigational drugs remains to
be determined, as does their link with the thermodynamics of their
binding andaqueous dissolution. However, the trend provided here sug-
gests that the approach developed here for telaprevir may be applicable
beyond protease inhibitors — or even peptidomimetic drugs in general.
Regardless of the structural origin of the potency–insolubility co-
nundrum, onemay generally leverage elements of the analysis detailed
here for its practical value in determining which insoluble compounds
can be improved bymanipulation of their solid forms andwhich cannot.
Computationally, one may determine if the insolubility is due to the
compound “liking its crystal” (i.e., favoring the crystalline state energet-
ically) or due to the compound “disliking water” (i.e., disfavoring the
aqueous state energetically) by calculating the sublimation and hydra-
tion free energies, respectively. By examining the relative values of the
solvation and sublimation free energies, it may be feasible to determine
if the origin of the insolubility is driven largely by the stability of the
compound's solid state or by unfavorable solvation in water. Com-
pounds that are deemed insoluble by virtue of their neat crystalline
solid states can be subjected to solid form investigations targeting theidentiﬁcation of higher energy/higher solubility solids such as co-
crystals and amorphous materials. Compounds with insolubility driven
by less favorable solvation in water can be spared from fruitless at-
tempts to identify higher energy/higher solubility solids. In this way,
computation can cut down on costly preclinical and clinical develop-
ment efforts that will lead to dead ends.
Fig. 4. provides a precise illustration of how sublimation and solva-
tion free energies taken togetherwith anunderstanding of the intestinal
permeability of a compound can be used to evaluate the potential for a
solid to achieve reasonable plasma concentrations upon oral adminis-
tration. Fig. 4A is a contour plot showing the fraction of a dose that is
absorbed into plasma as functions of the intestinal permeability (as
given by the permeation number) and solubility (as given by the dose
number). For compound X, with a permeation number of 1, the solubil-
ity of a neat crystalline form is too low to achieve any signiﬁcant absorp-
tion upon dosing. However, when the compound is made more soluble
(e.g., by rendering as a higher energy solid form such as an amorphous
form), it achieves substantial oral absorption (N30% bioavailability). For
compound Y, with permeation number = 10, a boost in solubility
doesn't provide for appreciable oral absorption (b10% bioavailability).
By estimating a compound's permeability through, for instance, a stan-
dard Caco-2 cell assay, the critical questions that can be answered by
calculations are as follows: 1) what effective solubility is necessary to
enable appreciable oral absorption?; and 2) can solubility be enhanced
by rendering the compound as a high energy solid, such as an amor-
phous or co-crystalline material? Simple oral absorption calculations
as depicted in Fig. 4A provide insight into the ﬁrst question. The calcula-
tion of the sublimation and solvation energies as in Fig. 4B helps answer
the second question together with experiments that test the solubility
advantage achieved from rendering a compound amorphous. The free
energy of solution is given by the sum of solvation and sublimation
free energies, and it can be assumed to ﬁrst approximation that the sol-
ubility advantage gained from rendering a compound amorphous ap-
plies to the sublimation free energy term. For example, Compound X
in Fig. 4B has 1 μM aqueous solubility under physiological pH and
temperature; its insolubility is largely due to its high sublimation energy
(51 kcal/mol) relative to its high solvation energy. If rendering the com-
pounds as an amorphous solid can lower the sublimation energy by
5 kcal/mol, it will enhance the solubility by 100 fold, leading to an ap-
preciable fraction absorbed (Fig. 4 A). In contrast, compound Y has
Fig. 3. Structure, function, and comparisons of the 1:1 telaprevir/4-HBA co-crystal. A) Telaprevir/4-HBA co-crystal structure, depicting ringmotifs with graph sets similar to telaprevir crys-
tals and NS3–telaprevir complexes— indicating that 4-HBA competes out telaprevirmolecules during crystal formation. Nitrogen atoms shown in blue, and oxygen in red. B–D) Structural
hierarchy of telaprevir/4-HBA: as in the neat crystal, telaprevir dimers assemble into rods (B), then sheets (C), but here, sheets are interrupted by rows of 4-HBA molecules (D). E) The
telaprevir/4-HBA co-crystal (black squares) showed 100-fold higher aqueous solubility (in simulated intestinal ﬂuid) than the commercial telaprevir tablet (purple squares). Solid lines
represent pharmacokinetic models that use solubilities in simulated gastric and intestinal ﬂuid as measured in vitro (black, co-crystal; blue, commercial tablet; violet, neat crystalline
telaprevir). F) For efavirenz, protein–drug and drug–drug complexes display nearly identical hydrogen-bonding patterns.
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(−23 kcal/mol) relative to its sublimation energy (44 kcal/mol). Ren-
dering this compound as an amorphous solid to decrease the sublima-
tion energy barrier by ~2 kcal/mol fails to improve its solubility
enough (Fig. 4B); the consequence is that its anticipated bioavailability
is less than 10% (Fig. 4A). Operationally, one can utilize estimates of the
intestinal permeability from an in vitro Caco-2 assay, estimates of the
solubility in the intestinal lumen from determinations of solubility in
simulated intestinal ﬂuids for crystalline and amorphous forms of a
compound, and/or estimates of the sublimation and solvation energies
from calculation, to help make a critical drug development decision:
to suspend further preclinical and clinical studies and avoid fruitless ex-
pensive and time consuming work that will not be successful, or to ad-
vance a compound with a high probability of a successful outcome.
When these computational approaches are combined with recent
advances in the ability to predict crystal structures, a path opens up to
compute aqueous solubility as well as its aqueous solvation and subli-
mation contributions prior to making compounds. Having this knowl-
edge for compounds at the medicinal chemistry design stage prior to
the actual synthesis allows one to evaluate the relative merits of pursu-
ing the costly synthesis and biological characterization of vast sets ofcompounds, only to ﬁnd out later that they cannot be rendered as solids
with sufﬁcient effective aqueous solubility to be developed as oral
drugs. It enables focus on compounds that are likely to succeed by im-
provements in aqueous solubility attained through solid phasemanipu-
lations. In these ways, the overall approach outlined here could
potentially increase the speed and success rate of drug discovery and
development dramatically; however, rigorous validation of computa-
tional methods, and sufﬁcient precision of the methods, will be neces-
sary to achieve the potential success rate improvements.
The potency–insolubility conundrum has led to countless power-
ful, promising medicines being abandoned long before a patient ever
takes them. It has also led to lengthy and costly failed efforts to for-
mulate insoluble compounds through solid form manipulations
that had little to no chance of succeeding in the ﬁrst place. Overcom-
ing this Catch-22, in at least some cases, could lead to less costly
drugs that reach patients more quickly. A recent study calculated
the cost of developing a new drug at $1.9 billion, 10-fold higher
than in the 1970s [25]. This growth in costs is not sustainable
indeﬁnitely; the need for smarter, more efﬁcient drug discovery is
immediate and intense. We hope that our approach will be one of
many contributions to this end.
Fig. 4. Computational evaluation of the potential for improvements insolubility and oral
absorption of compounds by altering their solid forms. A) Contour plot of bioavailability,
Fa, versus dose number, Do as a scaled measure of solubility and permeation number, Pn
as a scaled measure of gut permeability. Do is the ratio of the mass of administered dose
divided by volume of ﬂuid intake relative to the thermodynamic solubility. Pn is the ratio
of permeation rate through the gutwall relative to the transit rate through the small intes-
tine. Arrows depict the change in dose number and bioavailability due to transformation
from crystalline (c) to amorphous material (a). Compound X's bioavailability improves
sufﬁciently to warrant pharmaceutical development while Y's improves negligibly and
does not warrant development. B) Contours of solubility versus sublimation and solvation
free energy. As in A, arrows depict the transformation from crystalline to amorphous ma-
terial. Compound X is more soluble than Y, and its solubility increases more when trans-
formed from a crystalline (c) to an amorphous (a) material.
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The SI text details the procedures employed for singlemolecule crys-
tallography, determination of the thermodynamic parameters of disso-
lution, computational approaches, and pharmacokinetic assays in vivo.
The procedures are brieﬂy described here.5. Crystallography
Data were collected on a Bruker APEX II CCD diffractometer
(Bruker AXS, Madison, Wisconsin). The instrument is equipped
with a Cu Kα sealed-tube X-ray generator. Data are collected at
100 K with a nitrogen open ﬂow system or at room temperature.
Cu Kα seal tube radiation was used at 40 kV, 35 mA. Camera distance
is set at 5.25 cm. Oscillation photos aroundω and ϕ angles were col-
lected. Data were integrated and scaled by the APEX software. The
structures are solved and reﬁned with the SHELXTL package.6. Determination of the thermodynamic parameters of dissolution
We quantiﬁed the solubility of telaprevir by determining, with high-
performance liquid chromatography (HPLC), the concentration of the
compound in the aqueous portion of saturated suspensions of the crys-
talline material in water. van't Hoff analysis (i.e., the measurement of
solubility at varying temperature) provided the apparent enthalpy, en-
tropy, and heat capacity of dissolution. The apparent concentration of
telaprevir at equilibrium at a given temperature, however, depends on
the equilibria depicted in Fig. 1B, namely the hydration of the α-
ketoamide and epimerization of the chiral center at C-3. To derive the
actual values of the equilibrium constant between the crystalline and
solution forms of telaprevir, we measured the equilibrium constants
for i) hydration of theα-ketoamide (by solution phase nuclearmagnetic
resonance experiments) and ii) epimerization of the chiral center at C-3
(by HPLC using amethod that provided separation of the two diastereo-
mers). Measuring the temperature dependence of these equilibrium
constants provided estimates of the enthalpy and entropy of hydration
and epimerization, again, by van't Hoff analysis. Belowwe detail the ex-
perimental procedures and derive the expressions for estimating the
thermodynamic parameters that appear in Table 1 and the correspond-
ing errors in those estimates.
7 . Gas to solution transfer calculations
Three approaches were used to calculate the solvation free energies
of telaprevir and are presented for comparison. The methods are re-
ferred to as COSMO/SA [22], ZAP/SA [23], and DESMOND [21]. The ﬁrst
2 methods, COSMO/SA and ZAP/SA, split the solvation free energy into
two components— an entropic surface area term and an enthalpic elec-
trostatic term. The surface area term is the same in bothmethods and is
calculated using the method of Rizzo et al. which uses an atom type
weighted surface area function [28]. The enthalpy for the COSMO/SA ap-
proach was calculated using the density functional theory module
DMol3 with the Cosmo solvation model from within Materials Studio
[27]. The enthalpy for the ZAP/SA approach used OpenEye's Poisson
Boltzmann solver Zap with AM1BCC charges [23]. To account for multi-
ple conformations in the gas state, ten low energy conformers generat-
ed with OpenEye's Omega2 were used in the COSMO/SA and ZAP/SA
calculations to obtain an average result. The energy window for the
ten conformers was 2.7 kcal/mol. The third method used the Desmond
molecular dynamics/free energy perturbationmodule ofMaestro. These
calculations followed the approach described by Shivakumar and co-
workers [21]. For each Desmond run, the default parameters were se-
lected except for temperature (which varied between 278 and 318 K)
andwater model (TIP4pEW). The starting structure of a singlemolecule
of telaprevir was identical to that used for the crystal-to-gas calcula-
tions. The simulations comprised a 2 ns simulation of telaprevir solvated
in TIP4pEWwatermolecules in a box that extended 10Å from telaprevir
in each direction. The key output of the simulation was the “solvation
energy,” which corresponds to the free energy of transferring a single
molecule of telaprevir from aqueous solution to the gas phase. This
value was corrected to a standard state of 1 M using the following pro-
cedure. The output values for the volume of the simulation box at each
time step were averaged to determine the volume that contained a sin-
glemolecule of telaprevir, and this volumewas used to calculate the av-
erage concentration during the simulation. The free energy at the
reference state of 1 M was calculated using Eq. (3):
ΔG ¼ –RT ln c=cre fð Þ: ð3Þ
The error in the values of ΔGsolv is that determined by propagation
from the single molecule free energy and the variation in the volume
of the box and the simulated temperature over the course of the simu-
lation. The values of the solvation free energy estimated at different
temperatures were plotted as a function of the inverse of the simulation
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from the output data from each run (i.e., values of Tsim represent the av-
erage temperature over each time step of the simulation). The values of
the enthalpy of solvation were determined by van't Hoff analysis of the
computed free energies at different temperatures, while the data were
ﬁt by a nonlinear least squares method using three adjustable parame-
ters: Ksol, ΔH, and ΔCp at the reference temperature of 298.15 K. We
found that the solvation results from DESMOND, when combined with
our calculated gas to crystal results, best matched the experimental
data for the neat crystal form of telaprevir.
8. Gas to crystal transfer calculations
Gas to crystal transfer energies were calculated with the AMOEBA
(atomic multipole optimized energetics for biomolecular applications)
force ﬁeld [29] — available in the Tinker molecular modeling package.
AMOEBA attempts to approach quantum mechanical accuracy by
using an atomic ﬁxed charge model of monopole up to quadrupole ap-
proximation along with a polarization termwhich allows for charge re-
distribution in response to an external electric ﬁeld. To calculate equilib-
rium charge distributions, multiple rounds of self-induction of dipole
centers are carried out until convergence is achieved using the method
of Thole [30].
For non-trivial molecules, the electronic/torsional parameters re-
quired by AMOEBA must be pre-calculated using quantum mechanical
methods. For this study we used Gaussian 09 [31]. The full parameter
generating process can now be carried out automatically by use of the
programPoltype [32]— a python script which runs the QM calculations,
derives the electronic/torsional parameters, and obtains the ﬁnal van
der Waals and remaining bonded parameters from a lookup table. The
large number of atoms in telaprevir – 102 –made running the QM cal-
culations on the whole molecule unfeasible. Thus we fragmented
telaprevir and processed each fragment with Poltype. The resulting pa-
rameters for each fragment were then combined to create the ﬁnal
telaprevir parameter ﬁle. The fragments overlapped to some extent
and ranged in size from 15 to 45 atoms. To obtain gas phase conforma-
tions, each of the two independent molecules in the crystallographic
asymmetric unit was minimized in vacuum using Tinker's minimize
program with an energy convergence cutoff of 0.001 kcal/mol/A. For
gas phase, calculationswere performedon bothmolecules and the aver-
age was used. The crystallographic unit cell was minimized with
Tinker's xtalmin program using particle mesh Ewald summation for
electrostatic interactions. Due to the greater difﬁculty in obtaining con-
vergence with mutual polarization, an energy convergence cutoff of
0.3 kcal/mol/A was used.
The transfer of a molecule from gas to the crystal involves a loss of
translational and rotational degrees for freedom, a change in the vibra-
tional modes and frequencies, and the introduction of intermolecular
non-bonded interactions. The calculation of the translational, rotational
and vibrational transfer energies followed the general protocol laid out
by Brady and Sharp [20]. All calculations were at T = 298 K.
9. Pharmacokinetics
To determine whether the higher solubility of the telaprevir/4-HBA
co-crystal in vitro translated to increased absorption in vivo, we dosed
suspensions of crystalline telaprevir and of the co-crystal in methyl cel-
lulose or hydroxymethyl cellulose acetate succinate in rats at a dose
level of 30 mg/kg and compared the resulting pharmacokinetic proﬁles.
Then, to compare the absorption of the co-crystal with that of commer-
cially marketed telaprevir, we processed the co-crystal into tablets and
dosed these and commercial telaprevir tablets in male beagle dogs. Fi-
nally, to determine whether the increased exposure observed for the
co-crystal in dogs is actually due to the co-crystal's greater solubility
(as opposed to, e.g., increased permeability or decreased clearance),
we constructed a model using GastroPlus (version 8.0, SimulationsPlus, Lancaster, CA) with the following input parameters: permeability
(4.73 × 10−4 cm/s), solubility for the co-crystalline telaprevir in stom-
ach is 0.15 mg/mL and the intestine is 0.1 mg/ml, while for the com-
mercial tablet it is 0.1 mg/mL for both the stomach and the intestine.
The dissolution rates for the co-crystal and amorphous materials are
.24 and .48 ml/mg/min, respectively. Conventional physiological pa-
rameters for dogs (e.g., intestinal surface areas and transit times) were
used. The disposition parameters were constrained to be the same for
both co-crystalline and amorphous telaprevir with clearance of 0.64 L/
h/kg, ﬁrst pass extraction of 41%, plasma volume of 0.29 L, and K12,
K21, K13, and K31 as 2.25, 3.42, 0.94 and 0.16 h−1 respectively.
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